us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $84.91

    as of May 15, 2025
  • YTD RETURNS
    -1.02%

    as of May 15, 2025
  • Total Net Assets
    $623.05M

    as of May 15, 2025
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Fund Description

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Overview

Fund Highlights

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

  • Industry Leaders
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Sector Weightings (%) as at 04/30/2025

  • Sector

    % of Net Assets
  • Health Care

    99.84
  • Other/Cash

    0.16

Country Weightings (%) as at 04/30/2025

  • Country

    % of Net Assets
  • United States

    61.87
  • United Kingdom

    14.16
  • Switzerland

    5.34
  • France

    4.87
  • Japan

    4.72
  • Denmark

    4.55
  • Israel

    4.33
  • Other/Cash

    0.16

Distributions

Team

Literature

PPH